.Attribute Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ sophisticated breast cancer and energetic or steady mind metastases showed constant intracranial activity as well as systemic effectiveness of T-DXd.